Video

Our team behind the scenes at SXSW | Next steps: From molecule design to medicine

Following target identification and endotyping, we have the ability to design molecule compounds and progress these into clinical trials. In this final video, our team walks through our approach in this video to conclude the series from our SXSW keynote session.

Our team was able to identify lists of possible gene targets involved in disease by applying AI models on diverse sets of data such as scientific literature, patents, chemical databases, and patient data such as electronic health records or multi-omics datasets.

Following the generation of the list of targets, molecular design can start. Here we try to tackle an important aspect of making the drug brain penetrant. This is an important step where our team of scientists and machine learning researchers identify, design and test the best molecules.

The collaboration between our scientists and machine learning researchers gives us the ability to rethink and improve the process of drug discovery and development. Patients are at the heart of everything we do and this is reflected in our approach.

More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022